Document is current
Any future updates will be listed below
-
Authors
Simon, Florian https://orcid.org/0000-0002-2700-3717
Al-Sawaf, Othman https://orcid.org/0000-0001-9895-0570
Seymour, John F. https://orcid.org/0000-0003-2188-6835
Eichhorst, Barbara
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (524342988)
- License Information
-
More Information
Article History
Received: 16 July 2024
Revised: 13 November 2024
Accepted: 20 November 2024
First Online: 10 December 2024
Competing interests
: F.S. reports speaker honoraria from AstraZeneca and travel support from Lilly pharmaceuticals, as well as research funding by AstraZeneca (institution). O.A.-S. reports advisory board participation with Ascentage, AstraZeneca, AbbVie, Gilead, Janssen, and Roche; received speaker honoraria from Adaptive, AstraZeneca, AbbVie, BeiGene, Gilead, Janssen, and Roche; and received research funding from BeiGene, AbbVie, Janssen, and Roche. JFS reports honoraria from Hoffmann-La Roche, AbbVie, AstraZeneca, Janssen, Bristol Myers Squibb, Gilead, and BeiGene; consultancy fees from Hoffmann-La Roche, TG Therapeutics, Bristol Myers Squibb; participating on a data safety monitoring board or advisory board with Genor Bio, Hoffmann-La Roche, AbbVie, AstraZeneca, Janssen, Bristol Myers Squibb, Gilead, and BeiGene; speakers bureau with Hoffmann-La Roche, AbbVie, and BeiGene; and research funding from F Hoffmann-La Roche and AbbVie. B.E. reports grants and personal fees from F. Hoffmann-La Roche Ltd, AbbVie, AstraZeneca, BeiGene, and Janssen; reports personal fees from Celgene, Novartis, ArQule, Gilead, Oxford Biomedica (United Kingdom), Adaptive Biotechnologies, and Hexal.
